Modeling psychotic and cognitive symptoms of affective disorders: Disrupted latent inhibition and reversal learning deficits in highly stress reactive mice

Neurobiology of Learning and Memory

Volumn 94, Issue 2, 2010, Pages 145-152

  Knapman, A ^a   Heinzmann, J M ^a   Holsboer, F ^a   Landgraf, R ^a   Touma, C ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

Animal model; Cognition; Depression; Dopamine; Schizophrenia; Stress

Indexed keywords

DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CINGULATE GYRUS; COGNITIVE DEFECT; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; LATENT INHIBITION; LEARNING DISORDER; MALE; MOOD DISORDER; MOUSE; NONHUMAN; NUCLEUS ACCUMBENS; PERSEVERATION; PROTEIN EXPRESSION; PSYCHOSIS; TASTE AVERSION; VENTRAL TEGMENTUM;

EID: 77955585421     PISSN: 10747427     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nlm.2010.04.010     Document Type: Article

References (66)

1. Abi-Dargham A. Probing cortical dopamine function in schizophrenia: What can D1 receptors tell us?. World Psychiatry 2003, 2:166-171.
2. Ahima R., Krozowski Z., Harlan R. Type I corticosteroid receptor-like immunoreactivity in the rat CNS: Distribution and regulation by corticosteroids. Journal of Comparative Neurology 1991, 313:522-538.
3. Ahima R.S., Harlan R.E. Charting of type II glucocorticoid receptor-like immunoreactivity in the rat central nervous system. Neuroscience 1990, 39:579-604.
4. Aisa B., Tordera R., Lasheras B., Del Rio J., Ramirez M.J. Cognitive impairment associated to HPA axis hyperactivity after maternal separation in rats. Psychoneuroendocrinology 2007, 32:256-266.
5. Alves Fda S., Figee M., Vamelsvoort T., Veltman D., de Haan L. The revised dopamine hypothesis of schizophrenia: Evidence from pharmacological MRI studies with atypical antipsychotic medication. Psychopharmacology Bulletin 2008, 41:121-132.
6. Aronsson M., Fuxe K., Dong Y., Agnati L.F., Okret S., Gustafsson J.A. Localization of glucocorticoid receptor mRNA in the male rat brain by in situ hybridization. Proceedings of the National Academy of Sciences of the United States of America 1988, 85:9331-9335.
7. Austin M.P., Mitchell P., Goodwin G.M. Cognitive deficits in depression: Possible implications for functional neuropathology. British Journal of Psychiatry 2001, 178:200-206.
8. Baruch I., Hemsley D.R., Gray J.A. Differential performance of acute and chronic schizophrenics in a latent inhibition task. Journal of Nervous and Mental Disease 1988, 176:598-606.
9. Bielajew C., Konkle A.T., Merali Z. The effects of chronic mild stress on male Sprague-Dawley and Long Evans Rats: I. Biochemical and physiological analyses. Behavioural Brain Research 2002, 136:583-592.
10. Carlsson A., Lindqvist M. Effect of chlorpromazine or haloperidol on formation of 3 methoxytyramine and normetanephrine in mouse brain. Acta Pharmacologica et Toxicologica(Copenh) 1963, 20:140-144.
11. Carlsson A., Waters N., Waters S., Carlsson M.L. Network interactions in schizophrenia - Therapeutic implications. Brain Research Reviews 2000, 31:342-349.
12. Carpenter P.A., Just M.A., Reichle E.D. Working memory and executive function: Evidence from neuroimaging. Current Opinion in Neurobiology 2000, 10:195-199.
13. Clark L., Cools R., Robbins T.W. The neuropsychology of ventral prefrontal cortex: Decision-making and reversal learning. Brain and Cognition 2004, 55:41-53.
14. Cropley V.L., Fujita M., Innis R.B., Nathan P.J. Molecular imaging of the dopaminergic system and its association with human cognitive function. Biological Psychiatry 2006, 59:898-907.
15. Dal Toso R., Sommer B., Ewert M., Herb A., Pritchett D.B., Bach A., et al. The dopamine D2 receptor: Two molecular forms generated by alternative splicing. EMBO Journal 1989, 8:4025-4034.
16. de Kloet E.R., Joels M., Holsboer F. Stress and the brain: From adaptation to disease. Nature Reviews Neuroscience 2005, 6:463-475.
17. de Oliveira A.R., Reimer A.E., Brandao M.L. Dopamine D2 receptor mechanisms in the expression of conditioned fear. Pharmacology, Biochemistry and Behavior 2006, 84:102-111.
18. de Oliveira A.R., Reimer A.E., Brandao M.L. Role of dopamine receptors in the ventral tegmental area in conditioned fear. Behavioural Brain Research 2009, 199:271-277.
19. Dearry A., Gingrich J.A., Falardeau P., Fremeau R.T., Bates M.D., Caron M.G. Molecular cloning and expression of the gene for a human D1 dopamine receptor. Nature 1990, 347:72-76.
20. Ellenbroek B.A., Cools A.R. Early maternal deprivation and prepulse inhibition: The role of the postdeprivation environment. Pharmacology, Biochemistry and Behavior 2002, 73:177-184.
21. Floresco S.B., Zhang Y., Enomoto T. Neural circuits subserving behavioral flexibility and their relevance to schizophrenia. Behavioural Brain Research 2009, 204:396-409.
22. Gallagher P., Watson S., Smith M.S., Young A.H., Ferrier I.N. Plasma cortisol-dehydroepiandrosterone (DHEA) ratios in schizophrenia and bipolar disorder. Schizophrenia Research 2007, 90:258-265.
23. Gray N.S., Pickering A.D., Hemsley D.R., Dawling S., Gray J.A. Abolition of latent inhibition by a single 5mg dose of d-amphetamine in man. Psychopharmacology (Berl) 1992, 107:425-430.
24. Gray N.S., Pilowsky L.S., Gray J.A., Kerwin R.W. Latent inhibition in drug naive schizophrenics: Relationship to duration of illness and dopamine D2 binding using SPET. Schizophrenia Research 1995, 17:95-107.
25. Gross C.E., Ravenscroft P., Dovero S., Jaber M., Bioulac B., Bezard E. Pattern of levodopa-induced striatal changes is different in normal and MPTP-lesioned mice. Journal of Neurochemistry 2003, 84:1246-1255.
26. Guterman Y., Josiassen R.C., Bashore T.E., Johnson M., Lubow R.E. Latent inhibition effects reflected in event-related brain potentials in healthy controls and schizophrenics. Schizophrenia Research 1996, 20:315-326.
27. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 2000, 23:477-501.
28. Holsboer F., Ising M. Stress hormone regulation: Biological role and translation into therapy. Annual Review of Psychology 2010, 61(81-109):C1-C11.
29. Holsboer F., Liebl R., Hofschuster E. Repeated dexamethasone suppression test during depressive illness. Normalisation of test result compared with clinical improvement. Journal of Affective Disorders 1982, 4:93-101.
30. Holsboer F., von Bardeleben U., Wiedemann K., Muller O.A., Stalla G.K. Serial assessment of corticotropin-releasing hormone response after dexamethasone in depression. Implications for pathophysiology of DST nonsuppression. Biological Psychiatry 1987, 22:228-234.
31. Holtzheimer P.E., Nemeroff C.B. Advances in the treatment of depression. NeuroRx 2006, 3:42-56.
32. Ichikawa J., Li Z., Dai J., Meltzer H.Y. Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: Role of 5-HT1A receptor agonism. Brain Research 2002, 956:349-357.
33. Ising M., Kunzel H.E., Binder E.B., Nickel T., Modell S., Holsboer F. The combined dexamethasone/CRH test as a potential surrogate marker in depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2005, 29:1085-1093.
34. Jaber M., Dumartin B., Sagne C., Haycock J.W., Roubert C., Giros B., et al. Differential regulation of tyrosine hydroxylase in the basal ganglia of mice lacking the dopamine transporter. European Journal of Neuroscience 1999, 11:3499-3511.
35. Knapman A., Heinzmann J.M., Hellweg R., Holsboer F., Landgraf R., Touma C. Increased stress reactivity is associated with cognitive deficits and decreased hippocampal brain-derived neurotrophic factor in a mouse model of affective disorders. Journal of Psychiatric Research 2009.
36. Kuroki T., Meltzer H.Y., Ichikawa J. Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. Journal of Pharmacology and Experimental Therapeutics 1999, 288:774-781.
37. Lubow R.E. Latent inhibition. Psychological Bulletin 1973, 79:398-407.
38. Lubow R.E. Construct validity of the animal latent inhibition model of selective attention deficits in schizophrenia. Schizophrenia Bulletin 2005, 31:139-153.
39. Lubow R.E., Kaplan O., Abramovich P., Rudnick A., Laor N. Visual search in schizophrenia: Latent inhibition and novel pop-out effects. Schizophrenia Research 2000, 45:145-156.
40. Martinez R.C., Oliveira A.R., Macedo C.E., Molina V.A., Brandao M.L. Involvement of dopaminergic mechanisms in the nucleus accumbens core and shell subregions in the expression of fear conditioning. Neuroscience Letters 2008, 446:112-116.
41. Mawlawi O., Martinez D., Slifstein M., Broft A., Chatterjee R., Hwang D.R., et al. Imaging human mesolimbic dopamine transmission with positron emission tomography: I. Accuracy and precision of D(2) receptor parameter measurements in ventral striatum. Journal of Cerebral Blood Flow and Metabolism 2001, 21:1034-1057.
42. Muck-Seler D., Pivac N., Mustapic M., Crncevic Z., Jakovljevic M., Sagud M. Platelet serotonin and plasma prolactin and cortisol in healthy, depressed and schizophrenic women. Psychiatry Research 2004, 127:217-226.
43. Petrides M. Frontal lobes and behaviour. Current Opinion in Neurobiology 1994, 4:207-211.
44. Porter R.J., Gallagher P., Thompson J.M., Young A.H. Neurocognitive impairment in drug-free patients with major depressive disorder. British Journal of Psychiatry 2003, 182:214-220.
45. Quintin P., Thomas P. Efficacy of atypical antipsychotics in depressive syndromes. Encephale 2004, 30:583-589.
46. Rabin R.A., Sacco K.A., George T.P. Correlation of prepulse inhibition and Wisconsin Card Sorting Test in schizophrenia and controls: Effects of smoking status. Schizophrenia Research 2009, 114:91-97.
47. Rascle C., Mazas O., Vaiva G., Tournant M., Raybois O., Goudemand M., et al. Clinical features of latent inhibition in schizophrenia. Schizophrenia Research 2001, 51:149-161.
48. Rentesi, G., Antoniou, K., Marselos, M., & Konstandi, M. (2009). The effect of meternal deprivation on behavioural, neurochemical and neurobiological indices related to dopaminergic activity. Frontiers in behavioral neuroscience. In Conference abstract: 41st European brain and behaviour society meeting.
49. Reppermund S., Ising M., Lucae S., Zihl J. Cognitive impairment in unipolar depression is persistent and non-specific: Further evidence for the final common pathway disorder hypothesis. Psychological Medicine 2009, 39:603-614.
50. Reppermund S., Zihl J., Lucae S., Horstmann S., Kloiber S., Holsboer F., et al. Persistent cognitive impairment in depression: The role of psychopathology and altered hypothalamic-pituitary-adrenocortical (HPA) system regulation. Biological Psychiatry 2007, 62:400-406.
51. Ritsner M., Gibel A., Maayan R., Ratner Y., Ram E., Modai I., et al. State and trait related predictors of serum cortisol to DHEA(S) molar ratios and hormone concentrations in schizophrenia patients. European Neuropsychopharmacology 2007, 17:257-264.
52. Robbins T.W., Arnsten A.F. The neuropsychopharmacology of fronto-executive function: Monoaminergic modulation. Annual Review of Neuroscience 2009, 32:267-287.
53. Roesch M.R., Calu D.J., Schoenbaum G. Dopamine neurons encode the better option in rats deciding between differently delayed or sized rewards. Nature Neuroscience 2007, 10:1615-1624.
54. Rollema H., Lu Y., Schmidt A.W., Zorn S.H. Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation. European Journal of Pharmacology 1997, 338:R3-R5.
55. Ryan M.C., Sharifi N., Condren R., Thakore J.H. Evidence of basal pituitary-adrenal overactivity in first episode, drug naive patients with schizophrenia. Psychoneuroendocrinology 2004, 29:1065-1070.
56. Schmidt-Hansen M., Killcross A.S., Honey R.C. Latent inhibition, learned irrelevance, and schizotypy: Assessing their relationship. Cognitive Neuropsychiatry 2009, 14:11-29.
57. Shirayama Y., Obata T., Matsuzawa D., Nonaka H., Kanazawa Y., Yoshitome E., et al. Specific metabolites in the medial prefrontal cortex are associated with the neurocognitive deficits in schizophrenia: A preliminary study. Neuroimage 2009.
58. Solomon P.R., Staton D.M. Differential effects of microinjections of d-amphetamine into the nucleus accumbens or the caudate putamen on the rat's ability to ignore an irrelevant stimulus. Biological Psychiatry 1982, 17:743-756.
59. Touma C., Bunck M., Glasl L., Nussbaumer M., Palme R., Stein H., et al. Mice selected for high versus low stress reactivity: A new animal model for affective disorders. Psychoneuroendocrinology 2008, 33:839-862.
60. Touma C., Fenzl T., Ruschel J., Palme R., Holsboer F., Kimura M., et al. Rhythmicity in mice selected for extremes in stress reactivity: Behavioural, endocrine and sleep changes resembling endophenotypes of major depression. PLoS ONE 2009, 4:e4325.
61. Weiner I. Neural substrates of latent inhibition: The switching model. Psychological Bulletin 1990, 108:442-461.
62. Weiner I., Feldon J. The switching model of latent inhibition: An update of neural substrates. Behavioural Brain Research 1997, 88:11-25.
63. Wigger A., Sanchez M.M., Mathys K.C., Ebner K., Frank E., Liu D., et al. Alterations in central neuropeptide expression, release, and receptor binding in rats bred for high anxiety: Critical role of vasopressin. Neuropsychopharmacology 2004, 29:1-14.
64. Willner P. Chronic mild stress (CMS) revisited: Consistency and behavioural-neurobiological concordance in the effects of CMS. Neuropsychobiology 2005, 52:90-110.
65. Wong M.L., Licinio J. Research and treatment approaches to depression. Nature Reviews Neuroscience 2001, 2:343-351.
66. Young A.M., Joseph M.H., Gray J.A. Latent inhibition of conditioned dopamine release in rat nucleus accumbens. Neuroscience 1993, 54:5-9.